Articles tagged with Malaria Vaccines
Researchers have identified a toxin, glycosylphosphatidylinositol (GPI), that contributes to malaria's virulence and is now being explored for use in a vaccine. The anti-GPI vaccine has shown promise in mice, eliciting an antibody response and reducing immune reactions to the malaria parasite.
A new vaccine targets the parasite's deadly toxin, potentially providing longer-lasting protection against malaria. The vaccine has shown promise in animal trials, with mice surviving after being infected with the parasite when vaccinated against the toxin.
The National Institute of Allergy and Infectious Diseases (NIAID) has expanded its vaccine testing network, which has been a national resource for vaccine development since 1962. The new network will test vaccines against potential agents of bioterrorism and assess emerging hypotheses about vaccine-related adverse side effects.
A glycolipid called a-GalCer enhances long-lasting CTL mediated immunity against malaria in mouse models. It interacts with NKT cells to bridge innate and adaptive immunity.
Researchers at NIAID have successfully produced a malaria vaccine using transgenic mice that secrete the vaccine protein in their milk. The vaccine has shown promising results, with only one out of five immunized monkeys contracting the disease.
A new malaria vaccine, RTS,S/AS02, has demonstrated significant protection against natural P. falciparum infection in a randomised trial. The vaccine showed an overall efficacy of 34% after three doses, with increased effectiveness seen when a fourth dose was administered a year later.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a seven-year, $43.8 million contract to Science Applications International Corporation (SAIC) for malaria vaccine production and support services. This contract supports the acceleration of new malaria vaccine development, including clinical trials.
A new candidate vaccine targets multiple stages of the malaria parasite's life cycle, inducing a high level of antibodies that block invasion into liver cells and inhibit growth. The multicomponent vaccine offers potential for improved protection against different parasite strains.